OTCQB:EVFM

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

Retrieved on: 
Thursday, April 18, 2024
FDA, Patient, Lactic acid, Orange, Pregnancy, Woman, OTCQB, Hormone, Orange Book, Citric acid, Birth, Patent, SAN, Birth control

SAN DIEGO, April 18, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

Key Points: 
  • This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
  • The allowed claims cover methods of contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.
  • The patent, when issued, will be Evofem's fifth patent for Phexxi in the United States.
  • "This patent allowance attests to the innovation Phexxi brings to contraception and a woman's ability to protect herself from unintended pregnancy with no hormones."

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Retrieved on: 
Wednesday, March 27, 2024
Constitutional right, SAN, Research, Prior authorization, Acquisition, Lactic acid, Patient, Pregnancy, Fourth, Woman, Note, Security, WAC, OTCQB, Marketing, Citric acid, Medi-Cal, Beauty salon

SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:

Key Points: 
  • Highlights include:
    Delivered $18.2 million of Phexxi net product sales in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.
  • Sales and marketing expense was 64% of net sales for 2023, a key milestone for the Company and a significant improvement from prior years.
  • For the year ended December 31, 2023, net product sales were $18.2 million compared to $16.8 million in net product sales in the prior year.
  • For the three months ended December 31, 2023, net product sales were $4.8 million compared to $0.2 million in the prior year period.

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Retrieved on: 
Thursday, February 1, 2024
SAN, Growth, Citric acid, Lactic acid, OTCQB, Marketing

SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the Company's lowest total operating expenses since becoming a commercial stage company in 2020.

Key Points: 
  • SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate) , its hormone-free contraceptive gel, and the Company's lowest total operating expenses since becoming a commercial stage company in 2020.
  • Achieved preliminary net product sales in the range of $18.1 to $18.3 million in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.
  • Company reached a key milestone with net product sales higher than sales and marketing expense for 2023.
  • Evofem expects to report full results for the three- and twelve-month periods ended December 31, 2023, in mid-March 2024.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – EAR, IMGN, CVLY, EVFM

Retrieved on: 
Thursday, December 14, 2023
Empire, IMGN, Sale, Monteverde, EAR, ImmunoGen, AbbVie, OTC, Eargo, Security (finance)

Under the terms of the agreement, EAR shareholders will receive $2.55 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, EAR shareholders will receive $2.55 in cash per share they own.
  • Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.
  • Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.
  • Evofem Biosciences, Inc. (OTC: EVFM ), relating to its proposed sale to Aditxt, Inc. Click here for more information: https://www.monteverdelaw.com/case/evofem-biosciences-inc .

EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM

Retrieved on: 
Monday, December 18, 2023
Class Action Lawsuit, Professional Services, Legal, KSF, OTC, Sale

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Biosciences, Inc. (OTC: EVFM) to Aditxt, Inc. (NasdaqCM: ADTX) in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million.
  • KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

EVFM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Evofem Biosciences, Inc. Is Fair to Shareholders

Retrieved on: 
Tuesday, December 12, 2023
Class Action Lawsuit, Professional Services, Legal, Fraud, OTCQB, Advertising, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Evofem Biosciences, Inc. (OTCQB: EVFM) and Aditxt, Inc. is fair to Evofem shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Evofem Biosciences, Inc. (OTCQB: EVFM) and Aditxt, Inc. is fair to Evofem shareholders.
  • The investigation concerns whether Evofem and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Evofem shareholders; and (2) disclose all material information necessary for Evofem shareholders to adequately assess and value the merger consideration.
  • On behalf of Evofem shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Women, Other Health, Consumer, Health, Woman, Acquisition, Citric acid, Transaction, Security (finance), Form, Agreement, Male, FDA, Lactic acid, Birth, Security, Population health, Growth, Family, Female, Autoimmunity, Ministry of Social Affairs, Birth control, Renewable energy, Pharmaceutical industry

Pending a successful Transaction, it will also mark the establishment of a women's health mission within Aditxt's platform, aligning with global healthcare needs.

Key Points: 
  • Pending a successful Transaction, it will also mark the establishment of a women's health mission within Aditxt's platform, aligning with global healthcare needs.
  • Evofem is the creator of the first and only FDA-approved hormone-free contraceptive gel, Phexxi® (lactic acid, citric acid, and potassium bitartrate).
  • Like male contraception, female contraception should be adaptable to personal needs – not a daily burden, irrespective of actual necessity.
  • This innovation not only challenges the decades-long norm of daily hormonal contraception but empowers women with more personalized healthcare choices.

Evofem Biosciences Announces Financial Results for the Third Quarter of 2023

Retrieved on: 
Tuesday, November 14, 2023
Sale, DTC, Research, Employment, Citric acid, OTCQB, Food, Samsung Galaxy Note 10, Fourth, Fourth Amendment, Constitutional right, Exercise, Abbreviated New Drug Application, Weather, FDA, Marketing, Note, Lactic acid, Birth, Security, Private law, Growth, Fourth Amendment Protection Act, Contra, Cryptocurrency, Rare-earth element, Pharmaceutical industry, Security (finance), Generic drug, Lactic acid/citric acid/potassium bitartrate

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include:

Key Points: 
  • — Reduced loss from operations by 81% vs. Q3 2022 —
    SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023.
  • Highlights include:
    $5.1 million in net product sales of Phexxi® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023.
  • Third quarter total operating expenses were $8.7 million for 2023, a decrease of 65% as compared with the same period last year.
  • Narrowed loss from operations by 81% in the third quarter of 2023 as compared with the prior year quarter.

Evofem to Participate in the Virtual Investor Ask the CEO Conference

Retrieved on: 
Friday, October 13, 2023
Senior, OTCQB, Webcast, Conference, Virtual, SAN

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Senior Vice President, Investor Relations of Evofem will participate in the Virtual Investor Ask the CEO Conference on Tuesday, October 24, 2023 at 10:00 AM ET.

Key Points: 
  • -- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET --
    SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that Saundra Pelletier , Chief Executive Officer and Amy Raskopf , Senior Vice President, Investor Relations of Evofem will participate in the Virtual Investor Ask the CEO Conference on Tuesday, October 24, 2023 at 10:00 AM ET.
  • The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management.
  • Investors and interested parties will have the opportunity to submit questions live during the event.
  • A live video webcast of the event will be available on the Events and Presentations page of the Company's website ( evofem.com ).

Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire

Retrieved on: 
Wednesday, September 27, 2023
Abbreviated New Drug Application, Lactic acid, Paragraph, OTCQB, Certification, Orange Book, SAN, Citric acid, ANDA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Approved Drug Products with Therapeutic Equivalence Evaluations, Generic drug, Lactic acid/citric acid/potassium bitartrate

SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that Padagis Israel Pharmaceuticals Ltd. (Padagis) has withdrawn the Paragraph IV certification in its previously-submitted Abbreviated New Drug Application (ANDA) for a generic version of Phexxi® (lactic acid, citric acid and potassium bitartrate) and has instead converted to a Paragraph III certification. With this pivot to Paragraph III certification, rather than challenging the Phexxi patents and seeking approval of the ANDA prior to expiration of any of those patents, Padagis is instead now asking the U.S. Food and Drug Administration (FDA) to wait until after all the Phexxi patents expire before issuing final approval of the ANDA. The latest-expiring Phexxi patents do not expire until 2033.

Key Points: 
  • With this pivot to Paragraph III certification, rather than challenging the Phexxi patents and seeking approval of the ANDA prior to expiration of any of those patents, Padagis is instead now asking the U.S. Food and Drug Administration (FDA) to wait until after all the Phexxi patents expire before issuing final approval of the ANDA.
  • Padagis previously submitted its ANDA in April 2023 requesting permission to manufacture and market a generic version of Phexxi.
  • That ANDA contained a Paragraph IV certification, in response to which Evofem initiated patent infringement litigation against Padagis.
  • ' All four patents would need to expire or be deemed invalid or not infringed before a generic version of Phexxi could be marketed.